News Releases

Date Title and Summary
Toggle Summary electroCore to Participate in Upcoming Investor Conferences
ROCKAWAY, N.J. , March 12, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Strategy Officer, Joshua Lev , is scheduled to attend the 36 th Annual Roth Conference taking place at The
Toggle Summary electroCore to Announce Fourth Quarter and Full Year Ended December 31, 2023 Financial Results on Wednesday, March 13, 2024
ROCKAWAY, N.J. , March 05, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it will report financial results for the fourth quarter and year ended December 31, 2023 , after the close of the market
Toggle Summary electroCore Expands Intellectual Property Portfolio
ROCKAWAY, N.J. , Feb. 06, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating disorders associated
Toggle Summary electroCore Expands Intellectual Property Portfolio
ROCKAWAY, N.J. , Jan. 09, 2024 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to systems and methods for treating post-traumatic stress
Toggle Summary electroCore Expands Intellectual Property Portfolio
electroCore Granted Two New U.S. Patents ROCKAWAY, N.J. , Dec. 26, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received patent issue notifications from the United States Patent and Trademark
Toggle Summary electroCore Expands Intellectual Property Portfolio for Nerve Stimulation Technology
ROCKAWAY, N.J. , Dec. 12, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the United States Patent and Trademark Office has issued a patent related to a system for stimulating a nerve target in the head or
Toggle Summary Dr. Peter Staats to Host Analyst Day on the Science Behind gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) on Tuesday, November 21, 2023
ROCKAWAY, N.J. , Nov. 15, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that the Company’s Chief Medical Officer, Dr. Peter Staats will host an analyst day entitled “ Accessing the Power of Vagus Nerve
Toggle Summary electroCore Announces Third Quarter 2023 Financial Results
Record third quarter 2023 net sales of $4.5 million , an increase of approximately 128% over third quarter 2022 Company increases revenue guidance for full year 2023 to $15.0 million - $15.5 million  Company to host a conference call and webcast today, November 8, 2023 at 4:30 PM EST ROCKAWAY, N.J.
Toggle Summary electroCore to Participate in Canaccord Genuity’s MedTech, Diagnostics and Digital Health & Services Forum
ROCKAWAY, N.J. , Nov. 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that Company CEO, Dan Goldberger , is scheduled to attend the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services
Toggle Summary Data Highlighting Non-invasive Vagus Nerve Stimulation (nVNS) for Treatment of Symptoms of Gastroparesis Presented at 2023 American College of Gastroenterology Annual Meeting
Clinical Trial suggests nVNS can reduce the use of rescue medications for exacerbations of nausea due to Gastroparesis or Functional Dyspepsia ROCKAWAY, N.J. , Oct. 24, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today